drugset / Trial / NCT00054015

3-AP in Treating Patients With Advanced Prostate Cancer

NCT00054015

Phase 2 Completed Vion Pharmaceuticals
Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 3-AP in treating patients who have advanced prostate cancer that has been previously treated with hormone therapy.

Timeline

Start
2002-12
Primary completion
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Triapine Small molecule Intravenous

Indications